We were in Milan.
DeepCeutix exhibited at CPHI Milan 2026, stand 8S72. If we missed you on the floor, book a demo and we will run DeepC on your own molecule.
- Stand
- 8S72
- Where
- Hall 8, Start-up Market
- Venue
- Fiera Milano, Rho, Milan, Italy
- Dates
- 6 to 8 October 2026
- On stage
- Tuesday 6 October, Hall 8, 8F56
Book a demo.
Tell us what you are working on: the molecule, indication, stage or open question.
Bring a real problem.
Watch it run.
Each demo runs live on the molecule or product you name, over a call, and every number it returns links back to the regulatory record it came from.
Deformulation study
Name a reference product. DeepC returns a Q1/Q2 estimate of its composition, graded for confidence, with the dissolution target, the patents around it, and where to source each ingredient.
You leave with: A deformulation report (DF01): the best-estimate Q1/Q2 composition, the dissolution target, the patents around the product, where each ingredient can be sourced, and a graded confidence on every estimate.
See the study02Freedom-to-operate analysis
Bring a composition or an ANDA target. DeepC scores the patent risk, quotes the blocking claims line by line, and proposes design-arounds and a filing route.
You leave with: An FTO opinion (FTO01): claim charts with the claims in their own words, prior art, an overall risk rating, design-arounds, an expiry timeline and recommendations; then three design-around formulations.
See the study03Nitrosamine acceptable intake
Give it an API and its amine chemistry. DeepC derives the acceptable intake in ng/day under ICH M7(R2), assigns the CPCA category for a novel NDSRI, and drafts the control strategy.
You leave with: A nitrosamines risk assessment with its potency category, the acceptable intake in ng/day, and a control-strategy memo.
See the studyAlso available: extractables and leachables under ICH Q3E, formulation design against IID precedent, and the biologics suite. See the full platform.